Follow our progress

Study Supports Ongoing Phase 3 Program and Planned NDA Submission LONDON and RALEIGH, N.C., Dec. 16, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces ensifentrine met all safety

Enrollment in ENHANCE-1 48-week subset and ENHANCE-2  expected to complete around year-end 2021 ENHANCE Phase 3 program on track to report top-line data in 2022 Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc

LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present at the

LONDON and RALEIGH, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three and nine months ended September 30, 2021 on

Bronchodilation demonstrated with pMDI, consistent with DPI and nebulizer formulations LONDON and RALEIGH, N.C., Oct. 13, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the

Results demonstrate co-administration of fluconazole has minimal effect on ensifentrine pharmacokinetics LONDON and RALEIGH, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,

LONDON and RALEIGH, N.C., Aug. 31, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present a company

ENHANCE Phase 3 program on track to report top-line data in 2022 Up to $219 million strategic collaboration with Nuance Pharma in Greater China Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and RALEIGH, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA)

LONDON and RALEIGH, N.C., July 27, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present at the